Annual General Meeting of Shareholders

Telix Pharmaceuticals (ASX:TLX)

10.00am (Sydney time)

22 May 2024

Telix Manufacturing Solutions in Belgium


TLX250 SPECT image showing uptake in CAIX-positive lesions


TLX101-CDx PET image showing uptake in glioblastoma


illustration showing TLX591 binding to PSMA

Important information

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this presentation together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this presentation, whether as a result of new information, future developments or a change in expectations or assumptions.

Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been approved by the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada. Full United States prescribing information for Illuccix® can be found at http://illuccixhcp.com/s/illuccix-prescribing-information.pdf

This presentation has been authorised for release by the Telix Pharmaceuticals Limited Board of Directors. Unless otherwise stated, all figures are in AU$.

Telix

Genevieve Ryan
Company Secretary

Telix

Voting and questions

- A poll will be conducted on all resolutions
- Vote at any time during the course of the meeting
- The Virtual Meeting Online Guide provides detailed steps on how to vote and ask questions online – audio and written
- Chairman intends to vote all undirected votes in favour of the resolutions
- Poll results can be obtained later today by visiting the Company's website or the ASX
- Shareholders and proxies will be invited to ask questions

Telix

H Kevin McCann AO
Chairman

Telix

Board of Directors

H Kevin McCann AO

Non-Executive Director and Chairman

Christian Behrenbruch

Managing Director and Group CEO

Tiffany Olson

Non-Executive Director

Jann Skinner

Non-Executive Director

Andreas Kluge

Non-Executive Director

Mark Nelson

Non-Executive Director

Telix

Meeting agenda

01 Chairman’s address

02 CEO’s address

03 Formal items of business, including voting and questions

Telix

Annual General Meeting of Shareholders

Chairman’s address

H Kevin McCann AO

Telix

Annual General Meeting of Shareholders

CEO’s address

Dr Christian Behrenbruch

Telix



TLX250-CDx PET positive scan showing CAIX expression (Phase III ZIRCON study)

A global leader in theranostics and precision medicine

A unique, integrated radiopharma business

Therapeutics

Late-stage assets preparing for pivotal trials in prostate, kidney and brain cancer

Earlier stage assets include potential alpha therapies

Telix Manufacturing Solutions

Vertically-integrated, expanding global manufacturing footprint

Radioisotope supply

Deep partner relationships and a global supply chain

Access to raw materials

Telix

Integrated Theranostic Approach

See it. Treat it.

Precision medicine

Advanced imaging (diagnostics) informs treatment pathways and patient selection for therapy

Medical technologies

Interventional oncology drives deeper customer engagement

AI platform / dosimetry software

Deep radiopharma expertise

Broad development toolkit developing first-in-class or best-in-class products

Isotope agnostic (both alpha- and beta- emitters)

Validated and novel clinical targets

Therapeutics: Three key areas of focus

Markets with clear opportunities for radiation oncology to fulfil unmet medical needs



Telix

Precision medicine portfolio

Advanced imaging is a key enabler of therapeutic development

How advanced imaging supports our therapeutic portfolio:

- **“Companion”** for each therapeutic target
- **Facilitates patient selection for therapy** > optimisation of clinical trials and possible requirement for approved product
- **Validates targets** and derisks development and regulatory process for therapeutics
- **Compact clinical trials**, faster path to market
- **Early revenue generation** and commercial team specialisation to support therapeutics business

illuccix® (kit for the preparation of gallium Ga 68 gozetotide Injection)	Cornerstone of urology franchise, requisite for PSMA-targeting therapy
Zircaix[1] (zirconium Zr 89 girentuximab senvedoxam-crdi)	Targets CAIX, highly expressed in ccRCC and multiple hypoxic tumours
Pixclara[1] (floretyrosine F 18)	Initial focus in post-treatment monitoring, with potential to expand
Innovative PSMA imaging product	Expands access / patient reach for PSMA imaging, NDA filing H1 2024

Telix

1. Brand name subject to final regulatory approval

Our precision medicine model in prostate cancer

Imaging, devices and therapeutics across the care continuum



Telix Manufacturing Solutions

Vertical integration of supply chain and manufacturing

Equipped to deliver patient doses globally

- Global supply chain
- In-house EU production facility
- “AlphaLab” for specialty R&D
- Radiochemistry and clinical dose production



Global production, process development and R&D sites

Continuing to invest in in-house development and production capacity

- U.S. and EU isotope production footprint
- End-to-end process development and manufacturing technologies

Telix

Financial performance

Cash generation funding development of the pipeline

Quarterly Revenue, including Q1 2024[1]



2023 Key metrics

Revenue growth 214%

$502.5M

($160.1M 2022)

Gross margin improved

63%

(59%2022)

Profit after tax

$5.2M

(Net loss $104.1M 2022)

1. Q1 2024 revenues are unaudited, preliminary and based on management's estimate as of the date of this presentation and are subject to completion of the Company's financial closing procedures.

Recent achievements

ProstACT GLOBAL Phase III IND cleared for prostate cancer therapy trial commencement in the U.S.

Clinical differentiation and safety profile of TLX591 confirmed in ProstACT SELECT

Recruiting therapeutic trials of TLX250 (kidney) and TLX101 (brain)

Expansion of global manufacturing facilities: Optimal Tracers (U.S.) and production facility in Brussels South

North American production and processing enhanced with acquisitions of ARTMS and IsoTherapeutics



Proof of concept established for TLX592, alpha therapy candidate for prostate cancer

Ethics approval pending to commence biodistribution study for TLX300 program

Biologics License Application (BLA) for Zircaix®[1] commenced

Pixclara™[1] for brain cancer (glioma) imaging granted **Fast Track designation**

New Drug Application (NDA) for **new PSMA imaging product filing H1**

Telix

1. Brand name subject to final regulatory approval.

Near-term catalysts

- Progress late-stage therapeutic pipeline
- Advance next generation alpha theranostics
- Expand commercial imaging portfolio
- Vertically integrate supply chain

2024		H1 2025
ProstACT SELECT (TLX591) rPFS[1] data	Zircaix®[2] (TLX250-CDx) BLA completion	IPAX-2 and IPAX-Linz (TLX101) therapy studies readouts
STARLITE (TLX250 + immunotherapy) Phase 2 readout	Pixclara™[2] (TLX101-CDx) NDA submission	ProstACT GLOBAL (TLX591) Ph 3 interim readout
TLX300 clinical program commences in soft tissue sarcoma	Illuccix® Brazil, EU and UK approval decisions	TLX592 “alpha” therapeutic trial update
ProstACT GLOBAL recruitment at U.S. sites	New PSMA imaging product NDA submission	

Telix

1. Radiographic progression-free survival
2. Brand name subject to final regulatory approval.

.

Thank you

Telix